Purpose: To determine whether lower prevaccination CD4 counts decrease odds of immune development against hepatitis A virus/hepatitis B virus (HAV/HBV) among patients who receive the vaccine and examine the relationship between vaccine response and sex, race/ethnicity, health insurance status, tobacco use, substance abuse, or comorbidities. Methods: This study was performed among patients who received the standard dose for HAV and/or HBV vaccine. Results: Among 76 HIVinfected patients, immunity development to HAV or HBV increased as CD4 counts increased. In addition, males had greater vaccine response than females. Whites were observed to have higher rates of immunity than other races/ethnicities. Patients with private insurance had greater vaccine response than those with Medicaid, Medicare, or no insurance. Patients not experiencing hypertension and hyperlipidemia developed immunity more often than patients with these comorbidities. Substance abuse and tobacco use were also associated with lower vaccine response. Conclusions: Higher CD4 counts improved likelihood of patients developing an antibody response after vaccination.
Introduction
A weakened immune system, as observed among patients experiencing HIV, increases susceptibility to infectious diseases, including hepatitis. Hepatitis A and B vaccines are recommended for men who have sex with men (MSM) and injection drug users (IDUs). 1 Certain HIV risk factors also include injection drug use and unprotected sex between MSM. 2 Vaccinating persons among the general population against a range of diseases prevented approximately 2 million deaths in 2002. 3 Immunizations and vaccinations are considered to have one of the greatest impacts on public health 4 ; however, hepatitis A is still one of the most frequently reported diseases in the United States, despite approval of the vaccine in 1995. 5, 6 This study determined whether lower prevaccination CD4 counts decrease odds of immune development against hepatitis A or B virus (HAV/HBV) among patients who receive the vaccine. Our primary hypothesis was that a lower CD4 count is predictive of failure to develop immunity to HAV or HBV after vaccination. Exploratory analysis was used to investigate whether the development of immunoprotective antibody titers is associated with sex, race/ethnicity, health insurance status (a proxy for socioeconomic status [SES]), or comorbidities (eg, diabetes, chronic hepatitis C, hypertension, and hyperlipidemia), tobacco use, and substance abuse (ie, crystal methamphetamine, cocaine, marijuana, and alcohol).
Among HIV-infected patients, vaccination of patients whose CD4 counts are below a certain level might not result in an antibody response or development of protective immunity. However, among non-HIV-infected persons aged 17 to 70 years, the Twinrix (GlaxoSmithKline, Brentford, Middlesex, United Kingdom) vaccine has a 99.9% HAV and 98.5% HBV seroconversion rate when all 3 doses of the vaccine are completed. 7 Twinrix is a combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine. Studies have reported that high CD4 counts typically lead to HAV/HBV vaccine response among vaccinated HIV-infected patients. [8] [9] [10] [11] [12] However, no definitive literature has established exactly which CD4 count is the best point at which to administer vaccinations.
Our research also examined the relation between vaccine response and race/ethnicity, sex, health insurance status, substance abuse, and comorbidities. Of the limited number of studies that have examined demographic variables in relation to vaccine response, sex has been the primary variable of interest. Differences in demographic factors might affect ability to develop immunity if these variables can be proven to influence vaccine response. Mixed results have been reported regarding whether males or females have higher antibody response; therefore, this should be explored further. [13] [14] [15] Multiple studies have provided evidence that race/ethnicity and SES affect health markers (eg, CD4 count and viral load) among patients living with HIV/AIDS. Whether these variables affect vaccine response is unclear. 13, [16] [17] [18] [19] Only a limited number of studies have examined association between other comorbidities in relation to their effect on hepatitis vaccine efficacy among patients infected with HIV. 20 In reviewing the scientific literature related to drug and alcohol use in relation to CD4 counts, we reviewed 1 study reporting that persons using drugs or alcohol had statistically significant decreases in CD4 counts; however, no studies evaluated the effects of other substances on immunity development. 21 This analysis provides information for the medical community regarding HAV/HBV vaccination among patients living with HIV/AIDS. Vaccinating at optimal CD4 counts should lead to improved vaccine efficacy among HIV-infected patients, resulting in improved outcomes. Case patients were identified as those who developed immunity to HAV/HBV, and control participants were selected on the basis of not developing immunity to either HAV or HBV. Immunity was defined as having positive HbsAB or HA AB after vaccination. The patients' charts and the LabTracker system, an electronic medical records system, were used to obtain the data for analysis. Patients' medical charts were used to complete any information missing from the LabTracker database.
Methods

Study Design and Patients
Statistical Analyses
Demographic characteristics that were continuous measures were summarized with mean and standard deviation (SD). Categorical measures were described as frequency and percentage. Continuous measures were described with medians and ranges. Two-group pooled t test and chi-square tests of independence were used to make comparisons for continuous and categorical measures, respectively. Predictor variables used in these analyses included CD4 count (pre-and postvaccination), sex, race/ethnicity, health insurance status, comorbidities, and substance abuse. Patients who developed immunity, by evidence of a positive antibody test, were compared with those who did not; other variables were considered by using logistic regression. All statistical analyses were performed by using SAS version 9.1 (SAS Institute, Inc, Cary, North Carolina).
Results
A total of 451 patients were vaccinated at BCC during 2002-2007. Seventy-six patients were included in the final analysis as a result of lack of post vaccination HBsAB or HA AB titers.
Sociodemographic Profile
Demographic variables from included patients were compared with those excluded to ensure major differences in the sample did not exist (Table 1) . No differences were observed between patients included in the study and those who were not, except regarding AIDS status. The number of patients experiencing AIDS was higher in the included group (P ¼ .027). The majority of included patients were white, male, and had a mean age of 40 years (SD ¼ 9.2; Table 1 ).
Vaccine Response
Of those included in the study, 25 patients had been vaccinated against HAV, and 66 patients had been vaccinated against HBV, with 15 of the total 76 patients being vaccinated for both HAV and HBV. Fifteen of the 25 HAV-vaccinated patients (60%) developed immunity and 32 of the 66 (48%) HBV-vaccinated patients developed immunity. Patients who developed immunity to HAV, HBV, or both were grouped into 1 variable called immunity.
Demographics and comorbidities of patients who developed immunity were compared with those who did not develop immunity by using bivariate analysis (Tables 2 and 3 ). Only 2 patients reported experiencing heart disease; 1 patient reported cocaine use; 3 patients reported marijuana use; and 2 patients reported crystal methamphetamine use. Therefore, these variables were removed from the bivariate analysis because of the limited numbers available.
Analysis revealed that men were more likely to develop immunity than women. Patients with private insurance were more likely to develop immunity than those with Medicare, Medicaid, or no insurance coverage. Also, whites were more likely to develop immunity than non-whites. These results were varied when examining comorbidities and substance abuse.
No differences were identified between the ages at time of vaccination of those who developed immunity to either HAV or HBV and those who did not. CD4 counts of patients pre-and postvaccination were graphed by immune development for patients with both HAV and HBV by using box plots (Figures 1  and 2 ). The median CD4 count for patients who developed immunity was higher than those who did not for both HBV and the immunity group and for HAV ( Figures 1 and 2) . Median postvaccination CD4 counts were also higher for patients who developed immunity among all groups (Figures 1 and 2) .
On the basis of cutoff points used in previous literature, 9, 10, 22 Tables 5 and 6 display immune development for each group with CD4 count range indicated. Percentage of patients who developed immunity was highest for those with a CD4 count >400 cells/mm 3 (Table 4 ). To equalize the groups by size, all those with a CD4 count <400 cells/mm 3 were collapsed into 1 group and compared with those with a CD4 count >400 cells/mm 3 (Table 5 ). For these 2 groups, more patients developed immunity to HAV/HBV when their CD4 counts were >400 cells/mm 3 ( Table 5) .
Odds of immune development were determined from the results of the logistic regression. When examining the immunity group, which consisted of patients who developed immunity to either HAV or HBV, as CD4 counts increased, so did odds of immune development (Table 6 ). For every 50-and 100-unit increase in CD4 count, odds of immune development increased by 12% and 25%, respectively. Males were observed to have higher odds of immune development than females when controlling for all other factors in the model. Patients' insurance status demonstrated that those with private insurance had higher odds of immunity development, as were whites, when controlling for all other factors in the model. When controlling for the other variables in the model, patients with a comorbid condition (ie, AIDS, hypertension, or hyperlipidemia) had decreased odds of developing immunity. Alcohol use decreased odds of immune development as did tobacco use but only when comparing tobacco nonusers with tobacco users.
Discussion
Our results provide evidence of an association between CD4 count and development of immunity to HAV and HBV. As CD4 count levels increased among HIV-infected patients, so did their odds of developing immunity. Patients infected with HIV are recommended to be vaccinated when their CD4 counts are 200 cells/mm 3 , but on the basis of our results, higher confidence in vaccine efficacy can be achieved among patients at >400 cells/mm 3 because the highest percentage of patients developed immunity when they reached this level. A correlation exists between development of immunity and male sex, having insurance coverage, being white, not experiencing comorbidities, and not using alcohol or tobacco, which was determined through exploratory analysis. Persons with private insurance were observed to have higher odds of immune development, compared with those with no insurance or those with Medicare and Medicaid. Men were more likely to develop immunity than women when controlling for all other factors in the model, which was consistent with another previous study. 13 In addition, whites had higher odds of developing immunity than non-whites. Comorbidities (hyperlipidemia and hypertension) and having AIDS was associated with lower odds of immune development. Alcohol use was also associated with decreased odds of immune development. Smokers were less likely to develop immunity, compared with nonsmokers, but not when compared with former smokers. Why this correlation exists is unclear. Differences in racial/ethnic groups and insurance status also affected immune development. Previous studies have reported that race/ethnicity and insurance status, which was used as a marker for SES, are related. 23 Differences observed in immune development for these groups might be because of health concerns associated with being of a lower SES, 24 and because SES has been reported to be associated with race/ethnicity, this might affect the health of both groups. More research of these groups is needed to understand the complexity of this association among HIV-infected patients. Articles we reviewed provide results that agree with our primary research hypothesis that a lower CD4 count is predictive of failure to develop immunity to HAV or HBV after vaccination and our secondary hypothesis that immune development is associated with sex, race/ethnicity, health insurance status, substance abuse, and comorbidities. On the basis of our sample, a CD4 count cutoff level of 400 cells/mm 3 provides a greater confidence in the patient's ability to respond to HAV and HBV vaccination. We have also demonstrated that comorbidities can influence the odds of immune development as well as substance abuse; therefore, clinicians should be aware that patients experiencing these comorbidities have a decreased likelihood of responding. One limitation of this study was the sample size (76 case patients). With a larger sample, certain moderate differences might become statistically significant. Although these results are interesting, this study should be used as a pilot study for more research regarding this topic. Also, because of limited numbers, certain variables, including heart disease and cocaine, marijuana, and crystal methamphetamine use, were removed from analysis. A larger, more diverse sample should be used for a study of this topic to determine whether CD4 counts of 400 cells/mm 3 are actually the best for HAV/HBV vaccination.
Another limitation of this study was that a higher percentage of persons included in the study were experiencing AIDS (CD4 nadir <200 cells/mm 3 ) than those who were excluded. AIDS infection was observed to decrease a patient's odds of immunity development; therefore, because approximately 50% of these patients were experiencing AIDS, they might have needed higher CD4 counts than the general population to develop immunity. Performing this study among a group of patients experiencing AIDS and a group of HIV-infected patients not experiencing AIDS to determine whether a higher CD4 count is needed for immune development for those experiencing AIDS is recommended.
On the basis of the previous research and the results presented here, more research should be completed to evaluate the effects of a second dose of the vaccine. Fonseca reported that the double dose of the HBV vaccine had statistically higher response rates than the standard single dose series. 12 The extra expenditures needed to administer the second dose should be examined to determine whether they outweigh the expenditures of the single dose when doctors are forced to revaccinate patients because they do not respond to the first vaccination.
In addition, a study presented by Wilson reported that CD8 count was a statistically significant predictor of response to the HBV vaccine. 22 CD8 count was not collected in this study, but this variable, as well as viral load and CD4 count, should be explored to determine its effect on vaccine response. More research should be focused toward this topic because the information is critical to the HIV-infected population and the doctors and clinic staff who serve them. After a larger study is complete, a higher CD4 count for vaccination might be recommended to clinicians. Even on the basis of this information and the information from previous studies, we conclude that higher CD4 counts improve likelihood that patients will develop an antibody response after vaccination. Nevertheless, clinicians should not miss the opportunity to vaccinate on account of waiting for patients to reach a higher CD4 count before vaccination. Clinicians should consider focusing on changeable behaviors such as alcohol and tobacco avoidance and the prevention comorbidities as these have been shown to affect immune development. More research should be initiated to determine whether advocating for earlier highly active antiretroviral therapy (HAART) might prevent patients from having CD4 counts <200 cells/mm 3 .
In addition, this study reveals the relevance of monitoring antibody responses of patients living with HIV/AIDS after vaccination. If patients are not rechecked after they have been vaccinated, immune status to these organisms is unknown; followup is especially critical for patients with CD4 counts <400 cells/mm 3 . Of the patients included in the study, approximately half did not develop immunity after vaccination, and if not rechecked, these patients might not have the opportunity to be revaccinated. The majority of the patients excluded from the study did not have postantibody checks; therefore, for these patients, their HAV/HBV immunity status is uncertain, leaving them still at risk for contracting HAV or HBV.
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